Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Takeda Earlier Announced Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

By Benzinga Newsdesk
Today, 4:45 PM
The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT. No New Safety Signals Were Seen

TAK

Read More
1 minute read

HUTCHMED Announced License To Takeda To Develop And Commercialize Fruquintinib Outside China; Hutchmed To Receive $400M Upfront On Deal Closing; Up To 730M In Potential Future Milestone Payments Plus Royalties On Net Sales

By Charles Gross
Today, 4:45 PM
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK) to further the global development, commercialization and manufacture of fruquintinib outside of mainland China, Hong Kong and Macau, where it is market

HCM

Read More
4 minute read

‘Takeda’s Phase 3 AURORA Study Provides Evidence Of Maribavir’s Clinically Meaningful And Durable Effect In Cytomegalovirus Infection In Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint’

By Benzinga Newsdesk
Today, 4:45 PM
https://www.takeda.com/newsroom/newsreleases/2022/takedas-phase-3-aurora-study-provides-evidence-of-maribavirs-clinically-meaningful-and-durable-effect-in-cytomegalovirus-cmv-infection-in-hematopoietic-stem-cell-transpla

TAK